Macrogenics Inc MGNX
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
MacroGenics Announces Positive Interim Phase 1 Results for MGC026 and Highlights Plans to Initiate Front-Line Combination Study in SCCHN
-
MacroGenics Announces First Patient Dosed in Phase 1 Study of MGC030 in Patients with Advanced Solid Tumors
-
MacroGenics to Participate in the H.C. Wainwright 28th Annual Global Investment Conference
-
MacroGenics Reports Second Quarter 2026 Financial Results, Streamlined Operating Model and Strengthened Financial Position
-
MacroGenics Announces Achievement of $10 Million Milestone Following Gilead’s Exercise of Option to License Preclinical Bispecific Program
-
FDA Lifts Hold on Macrogenics Gynecological Cancer Treatment Trial
-
MacroGenics Study on Pause After Safety Issues
Trading Information
- Previous Close Price
- $3.63
- Day Range
- $2.13–3.57
- 52-Week Range
- $1.29–5.08
- Bid/Ask
- $2.26 / $2.31
- Shares Outstanding
- 63.70M
- Market Cap
- $143.33M
- Volume/Avg
- 4M / 626,829
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 0.93
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Macrogenics Inc is a clinical-stage biopharmaceutical company focused on developing antibody-based therapeutics for the treatment of cancer. The company is currently developing therapeutics utilizing multiple modalities, including antibody-drug conjugates (ADCs) and multi-specific antibodies (which it refers to as DART and TRIDENT molecules). It is advancing three proprietary product candidates in clinical development: lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload, and MGC028, an ADC that targets ADAM9 and delivers a novel TOP1i-based linker-payload. Its segment is developing and commercializing monoclonal antibody-based therapeutics.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Core
- Total Number of Employees
- 293
- Website
- https://www.macrogenics.com
Valuation
|
Metric
|
MGNX
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 3.33 |
Price/Sales | 0.93 |
Price/Cash Flow | — |
Price/Earnings
MGNX
Financial Strength
|
Metric
|
MGNX
|
|---|---|
Quick Ratio | 2.92 |
Current Ratio | 2.96 |
Interest Coverage | −5.80 |
Quick Ratio
MGNX
Profitability
|
Metric
|
MGNX
|
|---|---|
Return on Assets (Normalized) | −16.89% |
Return on Equity (Normalized) | −96.74% |
Return on Invested Capital (Normalized) | −41.12% |
Return on Assets
MGNX
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|bvK^F% | LOCK|yCRRV | $133B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|Kp%^P& | LOCK|TDzWg | $83B | |||
| Moderna Inc
MRNA
| LOCK|^JHy^P | LOCK|zP& | $80B | |||
| argenx SE ADR
ARGX
| LOCK|mT!n?Jg | LOCK|#py | $55B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|Ntj$%lJ | LOCK|BR | $45B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|!<#^V>Z | LOCK|t#JB | $30B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|m$bc!$Z | LOCK|FplHm | $28B | |||
| Incyte Corp
INCY
| LOCK|rDK@%QN | LOCK|%>l | $23B | |||
| BioNTech SE ADR
BNTX
| LOCK|jDc>&>b | LOCK|j@D | $22B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| LOCK|kYF>jy | LOCK|Bdx | $14B |
United States